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ABSTRACT
Background
In case-control studies, elevated levels of interleukins 6 and 8 have been found to be
associated with an increased risk of venous thrombosis (VT). Because of the design of these
studies, it remained uncertain whether these alterations were a cause or a result of the VT. In
order to distinguish between the two, we set out to measure the levels of six inflammatory
markers prior to thrombosis in a population-based cohort using a nested case-cohort design.
Methods and Findings
Between August 1995 and June 1997, blood was collected from 66,140 people in the second
Norwegian Health Study of Nord-Trøndelag (HUNT2). We identified venous thrombotic events
occurring between entry and 1 January 2002. By this date we had registered 506 cases with a
first VT; an age- and sex-stratified random sample of 1,464 controls without previous VT was
drawn from the original cohort. Levels of interleukins 1b, 6, 8, 10, 12p70, and tumour necrosis
factor-a were measured in the baseline sample that was taken 2 d to 75 mo before the event
(median 33 mo). Cut-off points for levels were the 80th, 90th, and 95th percentile in the control
group. With odds ratios ranging from 0.9 (95% CI: 0.6–1.5) to 1.1 (95% CI: 0.7–1.8), we did not
find evidence for a relationship between VT and an altered inflammatory profile.
Conclusions
The results from this population sample show that an altered inflammatory profile is more
likely to be a result rather than a cause of VT, although short-term effects of transiently elevated
levels cannot be ruled out.
The Editors’ Summary of this article follows the references.
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Venous thrombosis (VT) is a common and potentially lethal
disorder with an estimated incidence of one to three per
1,000 individuals per year [1–3]. The occurrence of venous
thrombotic events is inﬂuenced by acquired and inherited
risk factors (e.g., oral contraception and Factor V Leiden)
[4,5]. Combinations of these risk factors further increase the
risk to potentially high levels [6].
An important subgroup of risk factors comprises the levels
of procoagulant proteins. Several studies have shown that
elevated levels of coagulation factors VIII, IX, and XI increase
the thrombotic risk [7–9]. Genetic determinants of these high
levels have not been found, with the exception of the well-
known relation between the ABO blood group and factor VIII
levels. It is also possible that increased procoagulant levels are
acquired. Experimental studies in human volunteers injected
with low-dose endotoxin provide credence for this possibility,
as they showed increases in procoagulant protein levels in
parallel with an inﬂammatory response [10–14]. In other
studies we have found increased levels of inﬂammatory
markers in patients who had suffered from venous throm-
botic disease [15–17]. A scenario that links all these data
together is that an acquired inﬂammatory component is
either wholly or in part responsible for the increased levels of
at least some of the procoagulant proteins, and, either
directly or through this mechanism, causes VT.
The association between inﬂammation and VT leads to the
question of whether inﬂammation is the cause or the result of
VT.There are arguments forboth. Infavour of a causative role
is the above-mentioned possibility that inﬂammation may
increase procoagulant protein levels and thus increase the
prothrombotic state of the blood. In addition, it is well known
that inﬂammation may promote tissue factor expression on
white blood cellsand endothelial cells, thus providing a trigger
that may lead to thrombotic disease [18–22]. Other arguments
that could go with either role are: 1) the fact that levels of
inﬂammation markers are high in the acute phase of VT and
come down afterwards [23], and 2) the frequent occurrence of
inﬂammatory post-thrombotic syndrome [24,25].
Recent case-control studies showed that raised levels of
interleukins (IL) 6 and 8 are associated with a 2-fold risk for
both ﬁrst and recurrent thromboembolic events [15,16]. In the
Leiden Thrombophilia Study (LETS), both cytokines and
tumour necrosis factor alpha (TNF-a) were associated with a
2- to 3-fold increased risk of a ﬁrst VT, whereas the risk for IL-
10 seemed to be decreased [17]. These studies don’t answer the
question of whether inﬂammation is a cause or a result of the
event.Noprospectivestudieshaveyetbeenundertaken toﬁnd
out whether increased cytokine levels can be demonstrated in
thebloodbeforeavenousthromboemboliceventhasoccurred.
We tested the hypothesis that a chronic inﬂammatory state
following a proinﬂammatory stimulus, regardless of origin,
could precede future thrombotic events. In a population-
based cohort, we tested levels of cytokines (TNF-a, IL-1b, IL-6,
IL-8, IL-12p70) in blood samples obtained at inclusion, and
examined the association with the occurrence of subsequent
thrombosis.
Methods
Patients and Controls
Between August 1995 and June 1997, all inhabitants aged
20 y or older (n ¼ 94,194) in Nord-Trøndelag County (in
Middle Norway) were invited to participate in a population-
based health survey (HUNT2) [26]. HUNT2 covers a wide
range of topics such as chronic diseases, mental diseases,
medication, education, employment, physical activity, and
quality of life. The population in this county is considered
representative of the rest of the Norwegian population
regarding age and sex distribution, morbidity, mortality,
and income. It has a low geographic mobility, which makes it
suitable for a population survey with subsequent follow-up.
The overall participation rate was 71% (n ¼ 66,140) at
baseline (1995–1997), with a median age of 46 y (range 19–103
y) [26].
All consenting participants (n ¼ 66,140) underwent a
physical examination and ﬁlled out a questionnaire at
inclusion. The questionnaire contained questions about risk
factors for cardiovascular disease, lifestyle, quality of life, and
medication use. In addition, all participants were invited to
donate 7.5 ml of blood, and acceptable serum samples were
obtained from 65,291 participants (98.7%) [26].
The follow-up for VT was performed as follows: the
computerized diagnosis registries of all departments of the
only two local hospitals (Levanger and Namsos hospitals) were
checked for all in- and outpatient diagnoses containing ICD-9
and ICD-10 diagnostic codes for VT up until 1 January 2002.
We completed case ﬁnding by searching positive diagnostic
procedure codes for venography, duplex ultrasound, and
Doppler ultrasound from the registries of the radiology
departments in the two hospitals, and patients from Nord-
Trøndelag County discharged from St. Olav University
Hospital in the neighbouring county with diagnostic codes
of VT. This search led to the identiﬁcation of 2,136 cases with
a diagnostic code of VT. Hospital records were obtained, and
two physicians (I. Næss and S. Christiansen) validated each
case. Cases were included only if they fulﬁlled the following
criteria: deep venous thrombosis (DVT), an intraluminal
ﬁlling defect or no venous ﬁlling on ascending contrast
venography; or, no compressible venous segment or no venous
ﬂow in popliteal, femoral, or axillar veins on duplex ultra-
sound; or, a positive computed tomography scan or a positive
autopsy; for pulmonary embolus (PE), a ventilation-perfusion
scan with one or more segmental or subsegmental perfusion
defects with normal ventilation; or, a contrast defect on
pulmonary computed tomography scan; or, a positive autopsy.
This way, 1,271 cases with a validated diagnosis of deﬁnite and
probable VT were identiﬁed. These records were linked to the
HUNT2 cohort, and 798 (63%) cases were identiﬁed within
the cohort. We excluded all patients with previous VT,
enrolment in the HUNT2 cohort after the event, or eye-vein
thrombosis (n ¼ 283). As a consequence, 515 cases were
included, out of which 506 had blood samples available in
which reliable laboratory tests could be performed.
1,505 controls were randomly sampled from the baseline of
the HUNT2 cohort by frequency matching to the cases by sex
and 5-y age strata. 29 of them were excluded from the
subsequent data analysis because they had suffered one or
more thrombotic events before the drawing of a blood
sample. Another 12 had missing blood samples, leaving 1,464
controls for the analyses.
In a case-cohort design, every person in the source
population has the same chance of being included as a
control. Since our control group was sampled at baseline, 29
controls later became cases during the follow-up period. The
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estimate of the risk ratio, because all cohort participants from
the baseline contribute to the denominator in absolute risks
[27]. As a consequence of this design, the 29 controls that
later became cases were included in the case group as well as
in the control group.
Laboratory Measurements
Whole-blood samples were collected from non-fasting
participants at entry in the HUNT2 cohort, and within 2 h
the serum was separated from blood cells (centrifugation at
1,010 3 g) and stored in a refrigerator at 4 8C. All samples
were transported the same day in a cooler to the central
laboratory at Levanger Hospital and stored in the HUNT
biobank there the next morning at  70 8C. Samples taken on
Friday were frozen the following Monday morning after being
transported the same Friday evening [26]. We have no
indications that the time between phlebotomy and freezing
affected the levels of the inﬂammatory mediators.
Serum levels of IL-1b, IL-6, IL-8, IL-12p70, and TNF-a were
measured using a commercial multiplex bead assay that
allows accurate and reproducible measuring of multiple
cytokines in a single small serum aliquot [28,29]. To lower
the detection limit of the kit, we used procedures that
differed slightly from the recommendations of the manufac-
turer (BD Biosciences, Alphen aan den Rijn, Netherlands). In
brief, 10 ll of thawed serum was mixed with 10 ll of diluted
capture bead suspension and 10 ll of phycoerythrin-labelled
detection reagent in a sample tube [17]. After 3 h of
incubation in darkness, 200 ll of wash buffer was added
and the samples were centrifuged at 2003g. The supernatant
was aspirated and the bead pellet resuspended in 150 llo f
wash buffer, followed by analysis on a FACSCalibur ﬂow
cytometer. (BD Biosciences) [17]. In our hands, the detection
limit of these ELISAs was 2.5 pg/ml for all cytokines. With the
bead assays, the cytokine concentrations were often near the
concentration of the lowest calibrator, and, depending on the
analyte, the levels of cytokine in part of the samples remained
undetectable. The technicians were not aware of the case or
control status of the samples.
In some samples, outlier levels far above the standard
curves (up to 4% in cases and 3% in controls) were seen. We
believe that these measurements represent artefacts of the
procedure, and the results from such samples were excluded
prior to the analysis. In 12 controls (0.8%) and nine cases
(1.7%), the samples were missing, the volume of serum was
too low to perform cytokine assays, or the cytokine measure-
ments failed for technical reasons.
Statistical Analysis
We used univariate logistic regression to calculate odds
ratios and their conﬁdence intervals. Cut-off points were
detectable cytokine levels at the 80th, 90th, or 95th percentile
calculated in control participants. We stratiﬁed for sex, three
age categories (,50, 50–69, and  70 y of age), time between
blood sampling and the event, and whether the event was
idiopathic or secondary. A secondary event was deﬁned as an
event that occurred after major surgery or trauma, during
marked immobility (speciﬁed as paresis, paralysis, or .8ho f
travel), ante- or postpartum, during use of oral contraceptive
pills, or in people with a history of malignancy. Linear
regression was used to evaluate the relation between cytokine
levels and time until the events in cases.
All analyses were performed with SPSS version 11.0 (SPSS,
Chicago, Illinois, United States).
Consent
Participation was voluntary, and each participant signed a
written consent. All surveys were approved by the Norwegian
Table 1. General Characteristics of Cases and Controls
Category Characteristic Cases Controls
n (%) n (%)
Total 506 1,464
Sex Men 228 (45.1) 671 (45.8)
Women 278 (54.9) 793 (54.2)
Age groups 20–29 12 (2.3) 30 (2.1)
30–39 17 (3.4) 46 (3.1)
40–49 53 (10.5) 145 (9.9)
50–59 72 (14.2) 195 (13.3)
60–69 99 (19.6) 301 (20.6)
70–79 169 (33.4) 499 (34.1)
.80 84 (16.6) 248 (16.9)
Event DVT 320 (63.3) 15 (51.7)
a
PE 153 (30.2) 12 (41.4)
a
Both 33 (6.5) 2 (6.9)
a
Time from blood sample to event
b Median 33 mo (2 d to 75 mo)
aThe controls were collected at the entry of the HUNT2 study. During the follow-up, 29
controls got a first VT. They are included as both cases and controls. Controls with
previous events (i.e., events before the entry of the cohort) were excluded.
bTime in months from the date of blood sampling until the first objective event of VT in
cases only.
DOI: 10.1371/journal.pmed.0030334.t001
Table 2. Levels of Inflammatory Markers in Cases and Controls
Analyte Cases Controls
Detectable
n (%)
Range
(pg/ml)
Median
Detectable (pg/ml)
Detectable
n (%)
Range
(pg/ml)
Median
Detectable (pg/ml)
TNF-a 177 (35) 0–4507 15.2 499 (34) 0–3603 12.7
IL-1b 289 (59) 0–4523 49.9 850 (60) 0–4967 46.6
IL-6 194 (39) 0–4370 35.0 547 (38) 0–4784 39.9
IL-8 498 (99) 0–4193 17.7 1437 (98) 0–4420 17.9
IL-10 201 (40) 0–3786 11.0 582 (40) 0–4831 11.8
IL-12p70 283 (58) 0–4024 36.1 849 (60) 0–4934 30.0
DOI: 10.1371/journal.pmed.0030334.t002
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Results
General characteristics of the patients and controls are
listed in Table 1. The median age was 70 y in both cases and
controls at baseline. 45.1% of the cases were men, compared
with 46% in the control group (Table 1). Table 2 summarizes
the cytokine and chemokine data. TNF-a, IL-6, and IL-10
were detectable in approximately two-ﬁfths of the samples,
whereas IL-1b and IL-12p70 were detectable in three-ﬁfths of
the samples. IL-8 was unusual in that it was detectable in
almost all cases (99%) and in almost all the controls (98%) as
well (Table 2).
Whether markers were detectable or not was similar for
cases and controls. Consequently, the odds ratios calculated
based on detectable versus undetectable levels were about 1.0,
with narrow conﬁdence limits (Table 3). This indicates that a
detectable level of any of the markers surveyed in this study
was not related to a subsequent VT.
Table 3 lists the odds ratios that were calculated using P80,
P90, and P95 as cut-offs. All interleukins demonstrated the
same pattern, with no odds ratios exceeding 1.1 for the
proinﬂammatory interleukins (TNF-a, IL-1b, IL-6, IL-8, and
IL-12p70) and an odds ratio of 0.9 for the anti-inﬂammatory
IL-10.
We performed a sub-analysis on the samples that were
taken within 1 y before the event to see if levels were higher
shortly before a thrombosis occurred. They were not; if
anything, they tended to be lower. In an analysis of only cases,
IL-12 levels, for instance, showed a signiﬁcant decrease with
time closer to the event (Figure 1). IL-1 showed a very similar
pattern, while the other cytokines showed no clear trends in
values nearer to the event.
Using the 90th percentile in the control participants as a
cut-off point for all markers, again no effect was found when
men and women were assessed separately, or when a
distinction was made between an idiopathic and a secondary
event. We found no effect within the three age categories,
either (Table 4).
Discussion
We performed the current study to test the hypothesis that
circulating levels of proinﬂammatory cytokines or chemo-
kines are associated with a future event of VT. The data
negate this hypothesis, as we found no evidence, neither in a
primary analysis nor in post-hoc sub-analyses, that levels of
inﬂammation markers were increased in individuals who later
developed VT.
Due to the prospective design of this case-cohort study,
there was considerable variation in the time between the
blood sampling and the event (this varied between 75 mo and
2 d). Therefore, we could not fully rule out the possibility of a
sudden increase of inﬂammatory markers in hours or days
before a ﬁrst thrombosis. However, this possibility seems less
likely, considering the results of a sub-analysis of cases
developing VT in the ﬁrst year after blood sampling. These
patients showed no increase whatsoever in cytokine levels
shortly before the event.
We found a higher prevalence of detectable cytokines as
compared with the prevalence recently found in the control
group in the LETS, although the median levels were
Table 4. Odds Ratios and 95% Confidence Intervals for Subgroups with Inflammatory Markers above the 90th Percentile Compared
with Those below the 90th Percentile
Subgroup TNF-a IL-1b IL-6 IL-8 IL-10 IL-12p70
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Men 1.2 (0.7–1.9) 1.1 (0.6–1.8) 1.3 (0.8–2.1) 1.1 (0.7–1.8) 1.5 (1.0–2.3) 1.0 (0.6–1.7)
Women 1.0 (0.6–1.6) 1.0 (0.6–1.6) 0.8 (0.5–1.4) 0.9 (0.6–1.5) 0.7 (0.4–1.2) 1.1 (0.7–1.7)
Unprovoked events 1.0 (0.7–1.6) 1.3 (0.8–1.9) 1.1 (0.7–1.7) 0.9 (0.6–1.4) 0.9 (0.6–1.5) 1.3 (0.8–1.9)
Secondary events 1.1 (0.7–1.7) 0.9 (0.5–1.4) 0.9 (0.6–1.5) 1.2 (0.8–1.9) 0.9 (0.6–1.5) 0.8 (0.5–1.3)
Age ,50 y 0.7 (0.3–1.8) 1.1 (0.5–2.6) 0.7 (0.3–1.9) 1.0 (0.4–2.3) 0.5 (0.2–1.4) 0.9 (0.4–2.2)
Age 50–69 y 1.1 (0.7–2.0) 0.9 (0.5–1.6) 1.0 (0.6–1.8) 1.1 (0.7–2.0) 0.9 (0.5–1.7) 0.9 (0.5–1.7)
Age .70 y 1.1 (0.7–1.7) 1.1 (0.7–1.8) 1.0 (0.6–1.6) 1.0 (0.7–1.7) 1.1 (0.7–1.8) 1.2 (0.8–2.0)
DOI: 10.1371/journal.pmed.0030334.t004
Table 3. Odds Ratios and 95% Confidence Intervals for Detectability, and Cut-Offs at the 80th, 90th, and 95th Percentile of
Inflammatory Markers
Category TNF-a IL-1b IL-6 IL-8 IL-10 IL-12p70
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Detectable 1.0 (0.8–1.3) 1.0 (0.8–1.2) 1.1 (0.9–1.3) 1.5 (0.6–4.0) 1.0 (0.8–1.2) 0.9 (0.7–1.2)
P80 1.0 (0.8–1.3) 1.0 (0.8–1.3) 1.0 (0.8–1.3) 0.9 (0.7–1.2) 1.0 (0.7–1.2) 1.1 (0.8–1.4)
P90 1.1 (0.8–1.5) 1.1 (0.8–1.5) 1.0 (0.7–1.4) 1.1 (0.8–1.5) 0.9 (0.7–1.3) 1.0 (0.7–1.5)
P95 1.0 (0.6–1.5) 1.1 (0.7–1.8) 0.9 (0.5–1.4) 1.1 (0.7–1.8) 1.0 (0.6–1.6) 0.9 (0.6–1.5)
DOI: 10.1371/journal.pmed.0030334.t003
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and median age of 66 y and 70 y, respectively) (Table 1) could
be described as a substantially older population than the
LETS control group (mean age 47 y) [17]. As some cytokines
have been shown to increase with age while others remain
constant, it is possible that the higher prevalence could be
partly due to the high age of our cohort [30,31]. This does not,
however, explain the discrepancy of our study with the
increased risks of VT recently found in the LETS.
The LETS found that the risk of VT increased parallel to
several cytokines (TNF-a, IL-6, and IL-8). This was supported
by a decreased risk with increasing levels of anti-inﬂamma-
tory IL-10. In the LETS, the association between cytokine
levels and VT was found in samples that were collected after
the event. Therefore, a model in which the thrombosis is the
cause of subsequent cytokine release, and not the other way
around, is the most likely explanation of the results. Such a
model is also supported by the fact that C-reactive protein
levels were not associated with VT in the LITE prospective
study [32].
A potential limitation of the study is that the inﬂammatory
markers were evaluated with a method with lower sensitivity
than high-sensitivity ELISAs. For example, a high-sensitivity
ELISA of IL-6 may yield detectable levels in more than 90%
of the control samples. On the other hand, the claims that
inﬂammatory markers are a risk factor for VT were based on
studies of similar size with assays similar to ours.
In conclusion, we have investigated the role of cytokines
before development of a ﬁrst VT in the general population,
and found no evidence of an association, not even shortly
before the event. Therefore, it is unlikely that cytokine levels
play an important role in determining the risk of VT.
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Editors’ Summary
Background. Blood clots (thromboses) are a common medical problem,
especially in people who have been immobilized for a variety of reasons,
who have other medical or surgical conditions, or who take certain types
of drugs such as oral contraceptives. As well as these factors, various
genetic changes make it more likely that certain people will develop a
thrombosis. The most well known of these genetic changes is in a
clotting factor, Factor V. Instead of the normal clotting factor V, some
people have a variant known as Factor V Leiden, which makes them
more likely to develop a thrombosis. (It is so named as it was discovered
by researchers in Leiden, Netherlands.) Researchers are trying to find out
if other abnormalities, particularly in levels of substances involved in
inflammation, might make the chance of thrombosis more common.
Identifying such changes might make it easier to predict who might be
at risk of getting a thrombosis—for example, when a patient has to have
an operation—and thus give them appropriate preventative measures.
Why Was This Study Done? Previous studies have shown that the levels
of inflammatory substances, known as cytokines, are raised around the
time of a thrombosis. However, because of the design of these studies it
was not clear whether these alterations were a cause or a result of the
thrombosis. These researchers wanted to measure the levels of six
cytokines before thrombosis in a large group of people and follow them
to see if any particular level of cytokine made it more likely that they
would go on to develop a thrombosis.
What Did the Researchers Do and Find? During a three-year period
between August 1995 and June 1997, blood was collected from 66,140
people in the second Norwegian Health Study of Nord-Trøndelag
(HUNT2). Anyone who had a thrombosis between the start of the study
and the beginning of 2002 was identified—506 people in all. Blood
samples, taken from these people (cases) between two days and 75
months before the thrombosis happened, were used to measure levels
of a number of different cytokines (abbreviated to IL-1b, IL-6, IL-8, IL-10,
IL12p70, and tumour necrosis factor alpha [TNF-a]). These levels were
then compared with those in samples also taken earlier from 1,464
people who were similar to the cases but had no thrombosis (controls).
The authors found no evidence for a relationship between the chance of
getting a thrombosis and a change in any of these markers of
inflammation.
What Do These Findings Mean? It seems unlikely that any long-term
changes in levels of cytokines make any difference as to whether or not
people develop a thrombosis. Hence, any changes seen in previous
studies are most likely to have been the result of the thrombosis.
However, the researchers could not rule out that changes occurred in the
hours or days immediately before the thrombosis, although that seems
unlikely. In any case, the levels of these cytokines do not seem to be
useful as a clinical tool to predict who is at risk of thrombosis.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/101371/journal.pmed.
0030334.
  MedlinePlus encyclopedia entries on deep venous thrombosis and
pulmonary embolus
  Omni, a health information service in the UK run by the Resource
Discovery Network, has links to pages of information on venous
thrombosis
  The HUNT studies are described in this Web site
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